Modera Wealth Management LLC Lowers Holdings in Pfizer Inc. $PFE

Modera Wealth Management LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.1% in the 2nd quarter, Holdings Channel reports. The fund owned 62,093 shares of the biopharmaceutical company’s stock after selling 4,757 shares during the period. Modera Wealth Management LLC’s holdings in Pfizer were worth $1,505,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the first quarter worth $27,000. Curio Wealth LLC grew its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd purchased a new position in Pfizer in the first quarter valued at $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the second quarter worth about $29,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer during the 1st quarter worth about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on PFE shares. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.18.

Pfizer Stock Performance

NYSE:PFE opened at $24.45 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $138.99 billion, a P/E ratio of 13.00, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The firm has a 50-day moving average price of $24.74 and a two-hundred day moving average price of $24.37. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.